Jagannatha Aniruddha Tekkatte, Sriganesh Kamath, Devi Bhagavatula Indira, Rao Ganne Sesha Umamaheswara
Department of Neurosurgery, MS Ramaiah Medical College, Bangalore, India.
Department of Neuroanaesthesia, 3rd Floor, Faculty Block, Neurocentre, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka 560029, India.
J Clin Neurosci. 2016 May;27:68-73. doi: 10.1016/j.jocn.2015.08.035. Epub 2016 Feb 28.
The impact of hypertonic saline (HTS) on long term control of intracranial hypertension (ICH) is yet to be established. The current prospective randomized controlled study was carried out in 38 patients with severe traumatic brain injury (TBI). Over 450 episodes of refractory ICH were treated with equiosmolar boluses of 20% mannitol in 20 patients and 3.0% HTS in 18 subjects. Intracranial pressure (ICP) was monitored for 6days. ICP and cerebral perfusion pressure (CPP) were comparable between the groups. The mannitol group had a progressive increase in the ICP over the study period (p=0.01). A similar increase was not seen in the HTS group (p=0.1). The percentage time for which the ICP remained below a threshold of 20 mmHg on day6 was higher in the HTS group (63% versus 49%; p=0.3). The duration of inotrope requirement in the HTS group was less compared to the mannitol group (p=0.06). The slope of fall in ICP in response to a bolus dose at a given baseline value of ICP was higher with HTS compared to mannitol (p=0.0001). In-hospital mortality tended to be lower in the HTS group (3 versus 10; p=0.07) while mortality at 6 months was not different between the groups (6 versus 10; p=0.41). Dichotomized Glasgow Outcome Scale scores at 6months were comparable between the groups (p=0.21). To conclude, immediate physiological advantages seen with HTS over mannitol did not translate into long term benefit on ICP/CPP control or mortality of patients with TBI.
高渗盐水(HTS)对颅内高压(ICH)长期控制的影响尚未明确。当前这项前瞻性随机对照研究纳入了38例重型创伤性脑损伤(TBI)患者。超过450次难治性ICH发作分别在20例患者中用等渗剂量的20%甘露醇大剂量推注治疗,在18例受试者中用3.0% HTS治疗。颅内压(ICP)监测6天。两组间的ICP和脑灌注压(CPP)具有可比性。在研究期间,甘露醇组的ICP呈逐渐升高趋势(p = 0.01)。HTS组未观察到类似的升高(p = 0.1)。HTS组在第6天ICP保持低于20 mmHg阈值的时间百分比更高(63%对49%;p = 0.3)。与甘露醇组相比,HTS组血管活性药物使用时间更短(p = 0.06)。在给定的ICP基线值下,HTS推注剂量后ICP下降的斜率高于甘露醇(p = 0.0001)。HTS组的院内死亡率倾向于更低(3例对10例;p = 0.07),而6个月时两组间死亡率无差异(6例对10例;p = 0.41)。两组间6个月时二分法格拉斯哥预后量表评分具有可比性(p = 0.21)。总之,HTS相对于甘露醇所具有的即时生理优势并未转化为对TBI患者ICP/CPP控制或死亡率的长期益处。